Abstract 234P
Background
Cancer stem cells (CSCs) are a heterogeneous population of cancer cells with characteristics similar to normal stem cells, including the ability for self-renewal and differentiation. CSCs can differentiate into tumor-supporting cells potentially enabling metastasis, relapse, and chemoresistance. Complex networks involving several transcription factors, such as Nanog, Oct4, SOX2, and various miRNAs, have been identified to regulate CSC properties. The EMT is a process in which epithelial cells change their morphology, lose their polarity and acquire the migratory properties of mesenchymal cells. Many reports have shown that cells undergoing EMT can acquire stem cell-like characteristics and express markers of the EMT. However, the correlation between stemness and EMT is still unclear in oral squamous cell carcinomas.
Methods
Tumor tissues and adjacent clinically normal tissues were obtained from 50 patients with primary oral squamous cell carcinoma (OSCC) and 40 patients with recurrent OSCC. The expression of CSC markers Nanog, SOX2, and OCT4 and EMT markers SLUG and TWIST-1 were analyzed using immunohistochemistry. The mean immunoreactive score (staining intensity x proportion of positive cells) was calculated and compared in both tumor tissue and adjacent tissue. The immunohistochemical expression of these markers was correlated with pathological grade, lymph node metastasis, and AJCC staging of the tumor. Additionally, the expressions of SOX-2 and SLUG were evaluated in human OSCC cell lines using Western blot.
Results
The mean immunoreactive score of Nanog, SOX2, OCT4, SLUG and TWIST-1was higher in tumor tissues compared to adjacent tissue. Likewise, higher expression of both CSC and EMT markers was noted in recurrent OSCC than primary OSCC. High-grade tumors and those showing lymph node metastasis exhibited significantly increased expression of SOX-2, OCT4, and SLUG (p<0.01). Western blot analysis showed higher expression of SOX-2 and SLUG proteins in OSCC cells. Knockdown of SOX-2 and SLUG inhibited the migration and invasion of OSCC cells as demonstrated using transmigration assay.
Conclusions
The present study provides novel insights into the potential association between CSCs and EMT in OSCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03